Renata Hesse is co-head of the Firm's Antitrust Group. Her practice focuses on antitrust counseling, cartels and merger clearance. Ms. Hesse is frequently recognized as a leading and influential antitrust lawyer, with a particular emphasis on the intersection of antitrust and intellectual property matters in high-tech industries. In addition to her work on civil antitrust matters, Ms. Hesse also has an active practice involving criminal antitrust investigations, including advising clients on no-poach agreements and other wage-fixing and labor market investigations. She is Vice Chair and Diversity Officer of the American Bar Association's Antitrust Section and is a frequent speaker at antitrust and legal forums.

Ms. Hesse counsels some of the world's biggest companies on a range of high-stakes antitrust matters.

Ms. Hesse joined Sullivan & Cromwell following a distinguished career in government, including leading the Antitrust Division at the Department of Justice twice as Acting Assistant Attorney General and serving that division for more than 15 years. During her time at the Division, Ms. Hesse worked on a number of high profile transactions, as well as other key initiatives related to the licensing and enforcement of standards-essential patents.

Sullivan & Cromwell LLP provides the highest quality legal advice and representation to clients around the world. The results the Firm achieves have set it apart for more than 140 years and have become a model for the modern practice of law. Today, S&C is a leader in each of its core practice areas and in each of its geographic markets.

S&C comprises more than 875 lawyers who serve clients around the world through a network of 13 offices, located in leading financial centers in Asia, Australia, Europe and the United States. The Firm is headquartered in New York.

S&C Helps Seagen Obtain Global Antitrust and Regulatory Clearances for $43 Billion Acquisition by Pfizer

Seagen completed its $43 billion acquisition by Pfizer on December 14, after securing clearances from the Federal Trade Commission, the European Commission and other regulators. The $43 billion deal, announced in March, represents the largest-ever all-cash acquisition in the biopharmaceutical industry and will enable the combined company to accelerate the next generation of cancer breakthroughs.

S&C advised Seagen on U.S. antitrust and non-U.S. competition matters and coordinated the global regulatory processes. The European Commission unconditionally approved the acquisition under the EU Merger Regulation in October, concluding that the transaction would not raise competition concerns in the European Economic Area. The Commission stated that Òthe transaction was unlikely to have negative impact on prices, given that the parties' offerings are differentiated and complementary and that the markets for the treatment of examined are sufficiently competitive.Ó

In the United States, the FTC allowed the merger to proceed after Pfizer chose to donate its U.S. royalties for the bladder cancer treatment Bavencio to the American Association for Cancer Research to address FTC concerns.

The Seagen/Pfizer transaction is the second landmark healthcare deal within three months in which S&C'S global antitrust team has secured clearances.

S&C's Healthcare & Life Sciences Group has been a leader in the industry for nearly 30 years, having advised on more than $1.7 trillion of transactions in this sector.

The global S&C antitrust team advising Seagen included Renata Hesse, Samantha Hynes, Rick Pepperman, Clea McClellan, Caroline Black, David Whalen, Florence Kuhl Bamford, Julia Fotos, Jonathan Kwortek, Melike Tokatlioglu, Nicolas Britton and Tessa Griego in the United States and Michael Rosenthal, Justin Gibbs, Kolja Ortmann and Penelope Bergkamp in Brussels.